SCYX ข่าวฟอเร็กซ์
GSK, SCYNEXIS Ink Exclusive Licence Agreement For Brexafemme
GSK plc (GSK, GSK.L) and SCYNEXIS, Inc. (SCYX) announced Thursday they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC (RVVC).
RTTNews
|
578 วันที่ผ่านมา
